Immunome reports net loss for 2025

Immunome

03/03/2026 21:13

Overview

Biotechnology company reported a net loss of $212.4 mln for full-year 2025

Company raised $460.5 mln in December 2025 public offering, extending cash runway into 2028

Result Drivers

Underwritten public offering in December 2025 raised $460.5 million in gross proceeds

Company press release: ID:nBw7055Nta

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$212.39 mln
FY Income From Operations
-$224.11 mln
FY Operating Expenses
$231.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immunome Inc is $34.00, about 53.1% above its March 2 closing price of $22.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)